UNSPSC 51161573: Pranlukast hydrate

This classification denotes an anti-asthmatic agent and leukotriene antagonist with the molecular formula 2C27H23N5O4.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FR702N558K, chemically known as benzamide, n-(4-oxo-2-(2h-tetrazol-5-yl)-4h-1-benzopyran-8-yl)-4-(4-phenylbutoxy)-, hydrate (2:1), but more generally known as pranlukast hydrate, which bears US NIH Compound Identifier 5311184.

European Medicines Agency schedules pranlukast hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09998MIG. Most nations, for tariff purposes, schedule pranlukast hydrate under HS 29349990. SMILES: C1CCC(CC1)CCCCOC2CCC(CC2)C(=O)NC3CCCC4C3OC(CC4=O)C5[NH]NNN5.C1CCC(CC1)CCCCOC2CCC(CC2)C(=O)NC3CCCC4C3OC(CC4=O)C5[NH]NNN5.O.

UNSPSC 51161573 Pranlukast hydrate is a Commodity code covering a specific pharmaceutical product, a leukotriene receptor antagonist used in asthma and allergy treatment. State and local governments procure pranlukast hydrate primarily through centralized pharmaceutical purchasing programs, state health departments, and institutional healthcare providers including public hospitals, county clinics, and prison health systems. The product is typically acquired as part of formulary procurement cycles under generic or branded pharmaceutical contracts, often bundled with broader respiratory or allergy medication classes through cooperative purchasing vehicles or state pharmacy benefits management agreements. Pricing and availability are subject to FDA approval, manufacturer supply, and state Medicaid reimbursement schedules; purchasing volumes and specifications are driven by patient population needs and clinical evidence of efficacy compared to alternative leukotriene inhibitors.

The source provided contains no records of recent state and local solicitations under this code. Pranlukast hydrate procurement at the state and local level typically occurs through standing pharmaceutical contracts, GPOs (group purchasing organizations), or Medicaid purchasing programs rather than through discrete RFPs, RFQs, or ITBs; activity in this commodity code may not surface in posted procurement notices if acquisition occurs through existing master agreements or cooperative purchasing frameworks. Business development professionals should monitor state health department pharmaceutical acquisition calendars and Medicaid preferred-drug-list updates for formulary changes that may trigger new procurement activity, and engage directly with state pharmacy directors and institutional GPO procurement offices to identify sourcing opportunities.